U.S. markets closed
  • S&P 500

    4,486.46
    +15.09 (+0.34%)
     
  • Dow 30

    35,258.61
    -36.15 (-0.10%)
     
  • Nasdaq

    15,021.81
    +124.47 (+0.84%)
     
  • Russell 2000

    2,267.84
    +2.19 (+0.10%)
     
  • Crude Oil

    82.45
    +0.01 (+0.01%)
     
  • Gold

    1,764.40
    -1.30 (-0.07%)
     
  • Silver

    23.23
    -0.03 (-0.15%)
     
  • EUR/USD

    1.1614
    +0.0013 (+0.12%)
     
  • 10-Yr Bond

    1.5840
    +0.0650 (+4.28%)
     
  • GBP/USD

    1.3731
    +0.0054 (+0.39%)
     
  • USD/JPY

    114.2500
    +0.5730 (+0.50%)
     
  • BTC-USD

    61,679.20
    +764.77 (+1.26%)
     
  • CMC Crypto 200

    1,430.53
    -21.11 (-1.45%)
     
  • FTSE 100

    7,203.83
    -30.20 (-0.42%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Bharat Biotech's US Partner Ocugen Submits Covaxin Master File for FDA Review

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Ocugen Inc (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, has submitted a “Master File” to the FDA before seeking an emergency use authorization (EUA) in the U.S.

  • Ocugen submitted key information and data to date, including preclinical studies, chemistry, manufacturing, controls, and clinical studies as a Master File and input before a planned EUA submission.

  • As per Ocugen, it is still waiting for data from Bharat Biotech’s Phase-3 trials for Covaxin to apply for the EUA, which has been delayed due to the second wave in India.

  • The delay is primarily attributed to India’s decision to temporarily suspend the export of COVID-19 vaccines directing all resources domestically amid the resurgence of infections.

  • In February, Bharat Biotech entered into a definitive agreement with Ocugen to co-develop, supply, and commercialize, Covaxin for the U.S. market.

  • Ocugen said it is expecting Covaxin to roll out in the U.S. during the second half of the current year in an investor presentation.

  • The initial U.S. supply will be done by Bharat Biotech upon receiving authorization from the FDA, followed by a technology transfer to U.S. facilities.

  • Ocugen is targeting 100 million doses per annum beginning 2021.

  • Separately, The World Health Organisation has said “more information is required” from Bharat Biotech, which is seeking an emergency use listing for Covaxin.

  • Meanwhile, Bharat Biotech said that it had submitted 90% of the documents to WHO, and the remaining documents are expected to be submitted by June.

  • Price Action: OCGN shares are up 1.51% at $8.08 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.